FDA Approves EPINEPHRINE — ORIG Submission by ZYDUS PHARMS, Not disclosed in the FDA record.

Key facts

Regulatory context

This application was reviewed under FDA's ORIG submission pathway. An Abbreviated New Drug Application (ANDA) is the FDA pathway used to approve generic drug products. Instead of repeating the clinical efficacy and safety trials already performed for the original branded product, an ANDA sponsor must demonstrate that its generic version is bioequivalent to an already-approved reference listed drug and meets the same identity, strength, quality, purity, and manufacturing standards. FDA approval of an application does not itself guarantee ongoing marketing; sponsors remain subject to post-approval manufacturing inspections and adverse-event reporting requirements. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

What was approved

FDA's record shows ZYDUS PHARMS as the sponsor of EPINEPHRINE, with the generic name recorded as unspecified and dosage form SOLUTION. An Abbreviated New Drug Application (ANDA) is the FDA pathway used to approve generic drug products. Instead of repeating the clinical efficacy and safety trials already performed for the original branded product, an ANDA sponsor must demonstrate that its generic version is bioequivalent to an already-approved reference listed drug and meets the same identity, strength, quality, purity, and manufacturing standards. This specific application is submission type ORIG (submission number 1) under application number ANDA219832, with a submission status date of 20260914. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. This record is drawn directly from FDA's own approvals database rather than from company press materials. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

Frequently asked questions

What dosage form is EPINEPHRINE?

EPINEPHRINE is formulated as: SOLUTION.

What did FDA approve?

FDA's record shows anda approval for EPINEPHRINE (unspecified), dosage form SOLUTION, sponsored by ZYDUS PHARMS, under application number ANDA219832. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

What does the submission type mean?

An Abbreviated New Drug Application (ANDA) is the FDA pathway used to approve generic drug products. Instead of repeating the clinical efficacy and safety trials already performed for the original branded product, an ANDA sponsor must demonstrate that its generic version is bioequivalent to an already-approved reference listed drug and meets the same identity, strength, quality, purity, and manufacturing standards.

Is this product available now?

FDA's record lists a submission status date of 20260914. Availability, pricing, and distribution details beyond the submission status date are Not disclosed in the FDA record. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

Related enforcement actions

• Approval (recent): PHARMING — NDA approval: JOENJA (unspecified) →
• Approval (recent): TELIX PHARMACEUTICALS US INC — NDA approval: PIXCLARA (unspecified) →
• Approval (recent): MSN — ANDA approval: DASATINIB (unspecified) →
• Approval (recent): SCHOLAR ROCK INC — BLA approval: ISEMBYLD (unspecified) →
• Approval (recent): AUROBINDO PHARMA LTD — ANDA approval: ISOTRETINOIN (unspecified) →
• Approval (recent): RUBICON RESEARCH — ANDA approval: SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE (unspecified) →
• Approval (recent): BAYER HEALTHCARE — NDA approval: HYRNUO (unspecified) →
• Approval (recent): HETERO LABS LTD V — ANDA approval: IBRUTINIB (unspecified) →